The multi-centre, prospective analysis, involved 291 patients undergoing IVF treatment at two clinics in the US. Credit: denayunebgt via Shutterstock.

A study has been published highlighting that Alife Health’s artificial intelligence (AI) tool Stim Assist can be used to optimise the ovarian stimulation process for in vitro fertilisation (IVF) treatment.

The multi-centre, prospective analysis, published in Scientific Reports, involved 291 patients undergoing IVF treatment at two clinics in the US. The study evaluated Stim Assist’s ability to assist doctors in deciding the optimal dose of follicle-stimulating hormone (FSH) and timing of trigger injections during IVF treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Comparing outcomes between patients treated with AI assistance and those treated without it, the AI group showed a slight improvement in the number of mature eggs retrieved and a small reduction in FSH usage. While the results suggest AI could enhance IVF efficiency and outcomes, the improvements were not statistically significant. The researchers emphasised the need for further studies to validate these findings and explore the broader application of AI in IVF treatment.

Launched in 2022, Stim Assist – which draws on data from more than 40,000 prior cases – assists clinicians in their decision making to determine medication doses to stimulate the ovaries, producing mature eggs for IVF retrieval and fertilisation. These insights aim to extract the maximum number of mature eggs per cycle and lower medication costs. Alife also launched a patient-focused app in May 2023, which can be used to track medications, appointments, and insurance claims.

The San Francisco-based company raised $22m in a March 2022 series A funding round, setting out to conduct further clinical studies for its pipeline. The company has two other products in development, dubbed Embryo Assist, and Insights, a tool used monitor clinic KPIs in real time.

AI is making waves in nearly every corner of the healthcare sector. According to a report on GlobalData’s Pharma Intelligence Center, the AI market was worth $81.3bn in 2022. By 2030, it will have grown at a compound annual growth rate (CAGR) of 35.2% to $908.7bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData is the parent company of Clinical Trials Arena.

In the announcement accompanying the data, Alan B Copperman, a collaborator of the study and CEO of RMA of New York said: “The use of AI in IVF represents a significant advancement in reproductive medicine. By leveraging AI to optimize ovarian stimulation decisions, we can potentially improve IVF outcomes and streamline the treatment process for patients.”